{
    "nct_id": "NCT03135951",
    "official_title": "Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy",
    "inclusion_criteria": "* Newly diagnosed, histologically confirmed early-stage breast cancer, defined as operable Stage I to Stage IIIA breast cancer.\n* Candidate to receive adjuvant or neoadjuvant TC chemotherapy.\n* ANC ≥1.5x10^9/L\n* Platelet count ≥100x10^9/L\n* Hemoglobin >9 g/dL\n* Calculated creatinine clearance >50 mL/min\n* Total bilirubin ≤1.5 mg/dL\n* AST and ALT ≤2.5xULN\n* Alkaline phosphatase ≤2.0xULN\n* ECOG ≤2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of cervix) or life-threatening disease. If history of prior malignancies or contralateral breast cancer, must be disease free for at least 5 years.\n* Known sensitivity to E. coli derived products or known sensitivity to any of the products to be administered during dosing.\n* Concurrent adjuvant cancer therapy.\n* Locally recurrent/metastatic breast cancer.\n* Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 12 months prior to the administration of study drug.\n* Active infection, receiving antibiotics or any serious underlying medical condition which would impair the ability of the patient to receive protocol-specified treatment.\n* Prior bone marrow or hematopoietic stem cell transplant\n* Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.\n* Prior radiation therapy within 30 days prior to enrollment.\n* Major surgery within 30 days prior to enrollment.",
    "miscellaneous_criteria": ""
}